rilematovir + ciclosporin

Rilematovir + ciclosporin is a combination of two investigational or approved drugs. **Rilematovir** is an orally administered, small molecule inhibitor that targets the fusion (F) protein of respiratory syncytial virus (RSV), blocking conformational changes needed for viral entry and cell-to-cell fusion, thereby inhibiting viral replication[2][3][6][7]. Rilematovir is being developed primarily for RSV infection treatment; it demonstrates antiviral activity against RSV-A and RSV-B and has been studied in infants and children, showing a modest reduction in viral load and generally favorable safety profile[2][7]. **Ciclosporin** (also cyclosporine) is a calcineurin inhibitor, acting as an immunosuppressant by binding cyclophilin and inhibiting calcineurin, thus suppressing T-cell activation. The combination is not approved or standard, but potential drug–drug interaction exists via CYP3A4. Rilematovir (like similar fusion inhibitors) may interact pharmacokinetically with ciclosporin, as ciclosporin is metabolized by CYP3A4.

Other names

rilematovir + ciclosporin